Furthermore, investigations have indicated that utilizing the DNMT inhibitor decitabine in conjunction with doxorubicin effectively reduced DNMT1 activity, DNA methylation, and cancer cell proliferation [134]. The gene discussed is DNMT1; the disease is cancer.